BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer - Wikidata - wikimedia - TriplyDB

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

http://www.wikidata.org/entity/Q34621860

about

Genomic diversity of colorectal cancer: Changing landscape and emerging targets Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy Impact of somatic mutations on patterns of metastasis in colorectal cancer Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor.BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer.KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study.BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis.Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma.Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147 The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.Rapid, Microwave-Assisted Organic Synthesis of Selective (V600E)BRAF Inhibitors for Preclinical Cancer Research.BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.Pathway and network analysis in proteomics CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.The tumor border configuration of colorectal cancer as a histomorphological prognostic indicator.Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.Immunohistochemistry - microarray analysis of patients with peritoneal metastases of appendiceal or colorectal origin Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA.Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium Mutational analysis and clinical correlation of metastatic colorectal cancer.The colorectal tumor microenvironment: the next decade.A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer.Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.

P2860

Q26739052-C4743601-DA38-40ED-8284-EA9EDB700CCC Q26751035-9E4A0264-E880-49D6-A9F1-334BBB478F5B Q26772279-44C5B048-0ED6-49FE-B6D3-8AC1A107595A Q26828992-EF24CAE6-499F-4197-81C4-832FED886B09 Q27852942-FF21A8AD-869E-428E-8CF8-EC39FAD60601 Q27853121-DFAB8983-05AB-456C-AE8A-CE1C3768D23B Q27853216-C8F87467-3994-4E57-8D65-3EB8C99AEC90 Q30314225-EB0D211B-5837-4812-928C-A6D3CBEB6B94 Q30593460-44E8FF9F-FFB8-42C4-BECC-A5E427C603CD Q33615076-FBC68DA9-50AC-409B-902A-47970EA6DE66 Q33624491-FF13775E-EAF3-4C8A-98A8-B123218BDAF8 Q33679614-4CFA2AEC-8A37-4F16-B037-DD78A1BE12B9 Q33693309-81CB6280-F989-44A5-A0C9-1D69EE6F5B4F Q33740175-DD7E061A-0B0B-4C57-A5EF-B6A9244D100F Q33796513-23880942-12A9-4ECA-92DA-A8F2493E02CF Q33918101-F1D88FD6-F8B5-4155-8AC5-B1520E0D4EF5 Q33945376-9B6B44FD-A361-4A60-B388-F1560634F0DE Q33947880-12DF7E4B-2986-4730-B6F2-18184BCAA2DE Q34442771-79055039-B4D1-4AEC-A845-77E803ED7BD6 Q34488278-96B3E587-0A35-4D5B-A7C7-FE57D8F91931 Q34517338-DC3DF73F-6E58-4A6A-AB96-F4CBC4D62049 Q34557875-D539A701-CCCD-4E9B-9522-6ABD97B53A65 Q34620460-D4EEC671-16F9-4314-9A54-93FE1D4B07C9 Q34658263-0D2B5FB1-439C-4833-8EA4-B482E8F37ACC Q34660196-F83B7BE1-B1A9-4388-8601-32FEA8477CED Q34703562-6F1DD3E6-0BCE-4C6C-95A3-9815035D1DCF Q34748747-BFA75CD5-DAD7-4DF4-95E8-7A4949777449 Q34867868-F018E3B3-222F-45B0-8D4F-BB168225F6DF Q34976598-EB0C4799-61C9-4F79-8435-724B4CBED982 Q34982575-BB46554C-96A8-4311-9B25-E5D6D70F6865 Q34986042-DBA181EB-AD67-4EA9-BB56-B0F673F49698 Q35053271-D68D75C5-1B5D-460A-99CF-BA62B0911476 Q35082873-48026605-84E7-4A3C-96C7-FE881A93D6B6 Q35206661-87DC75CD-1A3E-407A-BB13-E85CB742FC7C Q35368335-D25769C2-4E9A-4186-8058-15DCA7B1F4EF Q35503680-CB4454E6-F4C9-4FC4-8045-08286BAA640F Q35677169-BF4453A7-8E9B-4CAC-B1C0-D04CE9A2E1A2 Q35874805-9B5216E1-A2A4-454E-8732-8E49BEFEFA55 Q35882193-207450F1-7C48-4826-8CB3-CDD36C416266 Q36086837-2C767F2B-38A8-41C7-A5F3-D8B3AA14B8A6

P2860

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

http://www.wikidata.org/entity/Q34621860

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@ast

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@en

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@nl

type

label

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@ast

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@en

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@nl

prefLabel

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@ast

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@en

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@nl

P1433

Q34621860-EE09DD44-DD67-4673-802C-185CE2384DF2

P1476

Q34621860-8D43973E-B86D-4BF3-AD19-21333A03FB2A

P2093

Q34621860-0D84378D-A815-4F1B-8F91-A37BEA926F23

Q34621860-1DBABDC7-A50C-4ABC-93BE-0EE81E4FC502

Q34621860-3F3AF4F8-E05B-49B3-BD73-567EE9403026

Q34621860-50D5A84D-AEFA-4A64-BAFC-3D5A1ED21219

Q34621860-53397B56-F0A2-4F8D-A301-005185FFDF09

Q34621860-69400177-CC90-41D1-A208-D75730B112B7

Q34621860-D0A34ACD-4F26-4AE0-ABF3-AB01C94C15B0

Q34621860-DE25F580-3EED-4504-9DD9-B64B72D6F860

Q34621860-E3049CA5-35C2-4FB9-8D05-CA1116B783A8

Q34621860-F50D68EA-A033-47C0-8B01-50B6B3210519

P2860

Q34621860-019F6CB2-6674-4997-A1E9-08196F4FD817

Q34621860-03A218A4-3ABC-4CE1-ADDF-D8AD8D2C2054

Q34621860-080B1E78-BCEF-4DEC-A277-51663987F434

Q34621860-11878850-9B81-4A75-AAD4-6ADF19092884

Q34621860-14F1DA7F-3F37-447B-8BD0-C23EB123E4E9

Q34621860-2179D81D-1733-4690-A713-033B8A2AABD7

Q34621860-2C9E0B65-5A55-40B8-87C5-415BE7B2EB76

Q34621860-32D89BF9-F5B8-494B-A9D4-A7A7940BAC6A

Q34621860-3928160A-A236-4AE2-9798-3F17DAB95E80

Q34621860-3AC198F8-1CEC-4375-B20E-3CD511E5CBD3

P2888

Q34621860-2137A107-B861-442D-A7D8-BEA7E2551FE3

P304

Q34621860-280834FA-AD50-4E2D-9920-2AECADF9B142

P31

Q34621860-9D9F72B7-8E3B-462A-BC2F-DBB3F89D64A8

P356

Q34621860-B8763F4D-252B-4BC5-B3C3-4C6CB3EFB3DB

P407

Q34621860-27E79CFA-8E3E-4418-9FE9-0624D97071A9

P433

Q34621860-8DCD706E-C12E-496B-B7EE-640ACC0711AE

P478

Q34621860-DEC4D220-8EC3-4E5A-8D74-B37D9A35A273

P577

Q34621860-3E9DBADE-F086-460F-932B-C58FE01EBC54

P5875

Q34621860-45ECC2B9-92E5-4A3E-A430-E361920B375A

P6179

Q34621860-A3DC999F-67A3-44FB-A975-3942DE0171E0

P698

Q34621860-4C5E5B78-7B04-46F6-B13F-F7B9E473AA1A

P921

Q34621860-CD1E90CA-4BDE-4EF0-8643-A95DD0342297

P932

Q34621860-6E64865D-87A1-47B2-AFB8-E9B61BEC78AD

P356

P1433

British Journal of Cancer

P1476

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

@en

P2093

A Mizota

http://www.w3.org/2001/XMLSchema#string

C Kondo

http://www.w3.org/2001/XMLSchema#string

D Takahari

http://www.w3.org/2001/XMLSchema#string

K Muro

http://www.w3.org/2001/XMLSchema#string

K Shitara

http://www.w3.org/2001/XMLSchema#string

M Nomura

http://www.w3.org/2001/XMLSchema#string

N Shibata

http://www.w3.org/2001/XMLSchema#string

S Utsunomiya

http://www.w3.org/2001/XMLSchema#string

T Ura

http://www.w3.org/2001/XMLSchema#string

T Yokota

http://www.w3.org/2001/XMLSchema#string

P2860

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Mutant KRAS, chromosomal instability and prognosis in colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.

The MAPK signalling pathways and colorectal cancer.

Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.

P2888

P304

856-862

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.19

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49802762

http://www.w3.org/2001/XMLSchema#string

P6179

1021787165

http://www.w3.org/2001/XMLSchema#string

P698

21285991

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3048210

http://www.w3.org/2001/XMLSchema#string